MedPath

Nerve Damage in Patients With HIV Infection Who Have Been Treated With Anti-HIV Drugs

Completed
Conditions
HIV Infections
Peripheral Nervous System Disease
Registration Number
NCT00017771
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Brief Summary

The purpose of this study is to find out what might increase nerve damage in people with HIV who have taken drugs for treatment of HIV disease. Another purpose is to see if nerve exams are done correctly before clinical research sites enroll HIV-infected patients.

Nerve damage is common in patients with HIV infection and can cause serious problems. The factors that place patients at risk are not well understood. This study will examine these factors in patients with advanced HIV infection and who have been taking anti-HIV drugs.

Detailed Description

Neurological complications in HIV infection are common and are significant sources of mortality and morbidity. The associated risk factors have not been clearly defined. Several studies have patients who are suited for analysis of peripheral neuropathy and can address the important clinical question of when a subject with asymptomatic neuropathy is most at risk for progressing to painful neuropathy. Some patients in this population with advanced HIV disease will likely have asymptomatic peripheral neuropathy at baseline, and will present an excellent opportunity for prospective study. Detailed quantitative assessments will be carried out to determine the incidence and course of peripheral neuropathy in this population. Risk factors for the development of new peripheral neuropathy, worsening of existing neuropathy, and progression to symptomatic peripheral neuropathy, such as CD4+ cell counts, HIV-1 viral load, and prior nucleoside analogue use, will be evaluated. The potential additive neurotoxic effects of hydroxyurea exposure in this population can also be analyzed.

HIV-infected patients are characterized for the presence or absence of neuropathy at \[AS PER AMENDMENT 03/05/02: screening\], baseline, Week 24, and Week 48. Entry variables are analyzed to determine predictors of progression from asymptomatic to symptomatic neuropathy or for worsening of symptomatic neuropathy. HIV-uninfected control volunteers have 1 visit \[AS PER AMENDMENT 03/05/02: or 2 visits\] for nerve conduction and Quantitative Sensory Testing (QST) evaluations to demonstrate proficiency with the testing methods prior to the enrollment of HIV-infected patients. HIV-infected patients are evaluated with the components of the Total Neuropathy Score (TNS) which includes signs (motor function, sensory function, and reflexes), symptoms (motor symptoms and sensory symptoms), QST (CASE IV - vibratory, cooling, and heat pain thresholds), and nerve conduction studies (sural nerve and peroneal nerve). Other evaluations include the Gracely Pain Scale and Visual Analog Scale pain diaries, paired skin biopsies from the right thigh and distal leg (total of 2), and peripheral blood lymphocyte analysis for quantitation of mitochondrial DNA content at entry and final study visit.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
100
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (18)

Univ of Alabama at Birmingham

๐Ÿ‡บ๐Ÿ‡ธ

Birmingham, Alabama, United States

UCLA CARE Ctr

๐Ÿ‡บ๐Ÿ‡ธ

Los Angeles, California, United States

Univ of Hawaii

๐Ÿ‡บ๐Ÿ‡ธ

Honolulu, Hawaii, United States

Wishard Hosp

๐Ÿ‡บ๐Ÿ‡ธ

Indianapolis, Indiana, United States

Univ of Washington

๐Ÿ‡บ๐Ÿ‡ธ

Seattle, Washington, United States

Methodist Hosp of Indiana / Life Care Clinic

๐Ÿ‡บ๐Ÿ‡ธ

Indianapolis, Indiana, United States

Univ of Rochester Medical Center

๐Ÿ‡บ๐Ÿ‡ธ

Rochester, New York, United States

Univ of Texas, Southwestern Med Ctr of Dallas

๐Ÿ‡บ๐Ÿ‡ธ

Dallas, Texas, United States

Beth Israel Med Ctr

๐Ÿ‡บ๐Ÿ‡ธ

New York, New York, United States

Johns Hopkins Hosp

๐Ÿ‡บ๐Ÿ‡ธ

Baltimore, Maryland, United States

Washington Univ School of Medicine

๐Ÿ‡บ๐Ÿ‡ธ

St Louis, Missouri, United States

Univ of Pennsylvania

๐Ÿ‡บ๐Ÿ‡ธ

Philadelphia, Pennsylvania, United States

Cornell Univ Med Ctr

๐Ÿ‡บ๐Ÿ‡ธ

New York, New York, United States

Univ of Colorado Health Sciences Ctr

๐Ÿ‡บ๐Ÿ‡ธ

Denver, Colorado, United States

Washington Univ / St Louis Connect Care

๐Ÿ‡บ๐Ÿ‡ธ

Saint Louis, Missouri, United States

Mount Sinai Med Ctr

๐Ÿ‡บ๐Ÿ‡ธ

Pittsburgh, Pennsylvania, United States

The CORE Ctr

๐Ÿ‡บ๐Ÿ‡ธ

Chicago, Illinois, United States

Indiana Univ Hosp

๐Ÿ‡บ๐Ÿ‡ธ

Indianapolis, Indiana, United States

ยฉ Copyright 2025. All Rights Reserved by MedPath